Download pdf
Revitalizing thalidomide: Advancements in drug design and therapeutic strategies
- 1 Monash University
* Author to whom correspondence should be addressed.
Abstract
Thalidomide, a drug initially introduced in the late 1950s, stands as a poignant reminder of the complexities of drug discovery. Initially hailed for its sedative properties, its widespread use led to a tragic medical disaster, with thousands of infants born with severe congenital malformations. This catastrophe prompted global reforms in drug testing and approval processes. However, the story of thalidomide took a turn as subsequent research unveiled its potential therapeutic applications, particularly its anti-inflammatory and immunomodulatory properties. This article delves into thalidomide’s transformative journey, from its tragic beginnings to its cautious reintroduction in medical therapeutics. The narrative underscores the balance between innovation, risk, and ethical responsibility in medicine. Furthermore, the article explores five cutting-edge technologies reshaping thalidomide’s therapeutic potential: molecular modifications and analogues, nanoparticle-based delivery systems, prodrug strategies, gene therapy integration, and enhanced formulations. Each technology offers unique avenues to enhance thalidomide’s efficacy, safety, and applicability. The advancements collectively signify the evolving landscape of pharmaceutical design, emphasizing the potential of tailored treatments that prioritize patient well-being. In conclusion, thalidomide’s journey from tragedy to therapeutic innovation serves as a testament to the resilience of medical science, highlighting the importance of continuous learning, adaptation, and responsible innovation in the realm of drug discovery.
Keywords
Thalidomide, Therapeutic Innovation, Molecular Modifications, Nanoparticle-Based Delivery, Ethical Responsibility
[1]. Magda Melchert, Alan List, The thalidomide saga, The International Journal of Biochemistry & Cell Biology, Volume 39, Issues 7–8, 2007, Pages 1489-1499, ISSN 1357-2725, https://doi.org/10.1016/j.biocel.2007.01.022. (https://www.sciencedirect.com/science/article/pii/S1357272507000441)
[2]. Fig, W.D. et al. (1999) ‘Thalidomide: A prodrug that inhibits angiogenesis’, Antiangiogenic Agents in Cancer Therapy, pp. 407–422. doi:10.1385/0-89603-641-3:407.
[3]. Li, Z. et al. (2022) ‘Thalidomide-based PT(IV) prodrugs designed to exert synergistic effect of immunomodulation and chemotherapy’, SSRN Electronic Journal [Preprint]. doi:10.2139/ssrn.4027269.
[4]. Rafeeq, M.M., Murad, H.A.S. Cystic fibrosis: current therapeutic targets and future approaches. J Transl Med 15, 84 (2017). https://doi.org/10.1186/s12967-017-1193-9
[5]. Abreu, N. and Waldrop, M. (2020) Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy [Preprint]. doi:10.22541/au.159363326.63434809.
[6]. Zhang, H., Qin, C., An, C. et al. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer 20, 126 (2021). https://doi.org/10.1186/s12943-021-01431-6
[7]. Alexandra V. Garafalo, Artur V. Cideciyan, Elise Héon, Rebecca Sheplock, Alexander Pearson, Caberry WeiYang Yu, Alexander Sumaroka, Gustavo D. Aguirre, Samuel G. Jacobson, Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives, Progress in Retinal and Eye Research, Volume 77, 2020, 100827, ISSN 1350-9462, https://doi.org/10.1016/j.preteyeres.2019.100827.
[8]. Manghwar, H. et al. (2020) ‘CRISPR/Cas Systems in genome editing: Methodologies and tools for sgrna design, off‐target evaluation, and strategies to mitigate off‐target effects’, Advanced Science, 7(6), p. 1902312. doi:10.1002/advs.201902312.
Cite this article
Yu,B. (2023). Revitalizing thalidomide: Advancements in drug design and therapeutic strategies. Theoretical and Natural Science,15,7-12.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Modern Medicine and Global Health
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).